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The biochemistry of the cell membrane and cellular signalling
systems have recently come to the fore as potential targets
for the discovery and development of new anticancer drugs
(Tritton & Hickman, 1990; Powis, 1991). As part of this new
focus natural products with potentially exploitable biological
properties receive increasing attention. The marine animal
product bryostatin 1 is a prototype of such agents. The most
prominent biochemical feature of this investigational drug is
its ability to activate the enzyme protein kinase C (PKC),
and this is probably intrinsically linked to its antineoplastic
activity. Bryostatin 1 is currently under phase 1 clinical
evaluation in the UK, and there is considerable uncertainty
as to the potential therapeutic and toxicological implications
of PKC modulation. It is especially unclear how pharma-
cological alteration of the properties of such a crucial and
ubiquitous enzyme could be selective, because normal cells,
as well as their diseased counterparts, would be susceptible to
disruption (Tritton & Hickman, 1990). In view of this uncer-
tainty and of the prospect of more agents of similar struc-
tural and biological complexity entering the oncologist's
chemotherapeutic armamentarium it seems appropriate to
summarise the scientific basis upon which the potential use of
PKC modulators such as bryostatin 1 in cancer treatment is
founded. This is the aim of the commentary. In particular
recently discovered characteristics of PKC activity and
regulation are highlighted as far as they might eventually
lead to selective intervention by drugs.
PKC activity
The cellular effects of many growth factors and hormones are
brought about by receptor-mediated hydrolysis of the mem-
brane phospholipid phosphatidylinositol 4,5-bisphosphate.
This hydrolysis results in the production of inositol 1,4,5-
trisphosphate and diacylglycerol. Both molecules function as
intracellular second messengers. Inositol 1,4,5-trisphosphate
releases Ca2+ from internal stores at the endoplasmic reti-
culum, and diacylglycerol activates PKC. PKC is an enzyme
family with serine/threonine kinase function which regulates
many cellular processes, including cell proliferation and
differentiation (Nishizuka, 1989). PKC activity is dependent
on the presence of phospholipids, and most PKC isozymes
require Ca2" for optimal activity. Most activated PKC is
found at the cell membrane, but a fraction has been located
associated with the nucleus (Shimizu & Shimizu, 1989).
Nuclear PKC is possibly of high functional importance as
stimulation of PKC elevates, directly or indirectly, the
activity of nuclear proto-oncogenes such as c-fos, and c-jun,
sometimes referred to as 'immediate early genes'.
The signal transduction pathway which operates via PKC
than other types of cancer cells (Hirai et al., 1989), but
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appears to be essentially ubiquitous. But the extraordinary
diversity of responses to PKC activation could be explained
by the multiple gene products that constitute the PKC family
(a,jB,ze,A,g, and their tissue-selective distribution
(Nishizuka, 1988; Parker et al., 1989; Stabel & Parker, 1991).
Whilst it has not yet been possible to ascribe specific cellular
responses to the activation of individual PKC isotypes, in-
vestigation of their properties has provided evidence for func-
tional heterogeneity: PKC isozymes differ from each other in
substrate specificity (Schaap & Parker, 1990; Marais &
Parker, 1989) and in their dependency on Ca2" (Schaap et
al., 1989; Akita et al., 1990) or on diacyglycerol/phospholipid
(Ono et al., 1989) for maximal activation.
Is there then a difference between tumours and normal
tissues in levels or isozyme content of PKC, which could be
therapeutically exploited? The relevant literature is not easy
to interpret, which applies also to many other aspects related
to PKC. PKC expression has been studied in leukaemias,
melanomas, and breast, colon and lung cancers. Subtle but
significant differences have been observed. Of the three major
PKC isozymes a, P and y, which were found in human
leukaemia cells the former two were present in all types of
leukaemic cells (Komada et al., 1991). Acute myelocytic
leukaemia cells expressed both types at equal levels, whereas
in lymphoid cells expression of PKC-P was more abundant
than that of PKC-a. PKC-y was expressed in lymphoid
leukaemia, but only sporadically in acute myeloid leukaemia
cells. A comparison of murine non-transformed melanocytes
and transformed melanoma cells is particularly instructive, as
subcellular distribution and overall levels of PKC differed
depending on cell type and proliferation state (Brooks et al.,
1991). In quiescent melanocytes most PKC activity was in
the cytosol, whereas in the melanoma cells the majority of
PKC activity was located in the membrane fraction. Total
PKC levels were higher in quiescent melanocytes than in
melanoma cells, which in turn contained more enzyme than
proliferating melanocytes. These results indicate that overall
PKC levels are related to proliferative capacity and that
cytosolic enzyme might play an anti-proliferative role. Nor-
mal human melanocytes did not express PKC-a, -0, or -'y,
whereas the a isozyme was expressed in primary and meta-
static melanoma (Becker et al., 1990). Incongruous with these
results Yamanishi et al. (1991) did find PKC-x, -P and -a in
primary melanocytes, and they reported that PKC isotype
gene expression changed during the progression of
melanocytes to metastatic melanoma. PKC levels in surgical
specimens of human breast tumours were almost 3-fold the
enzyme activities in normal breast tissue obtained from the
same patients (O'Brian et al., 1989). In contrast, in human
colonic adenoma or carcinoma samples PKC activity was
significantly reduced as compared to adjacent mucosa tissue
and mucosa in control subjects (Kopp et al., 1991). PKC
activity in normal colonic mucosa from patients with colorec-
tal cancer was only a third to one half of levels in patients
without cancer (Sakanoue et al., 1991). Human lung car-
cinoma cells appear to possess higher activities of PKC-x
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than other types of cancer cells (Hirai et al., 1989), but
PKC-x is also the most abundant isoform of PKC in normal
tiusues and cells (Nishizuka, 1989). Viewed together the data
on PKC levels and expression suggest that differences in
PKC activity and isotype composition are dependent on
origin of tissue and type of malignancy, and that generalisa-
tions as to which PKC-isozymes play a role in specific neo-
plasias cannot be made yet.
PKC activators and growth arrest
In many cells activation of PKC triggers mitogenesis. How-
ever in others, mainly malignant cells of human origin, it
causes the reverse, cytostatis or cytotoxicity. This observation
is germane to the argument that PKC activation might be of
therapeutic benefit. Therefore in the following known
endogenous and exogenous PKC activators and cell types in
which they cause growth arrest are briefly reviewed. Diacyl-
glycerols are the major cellular PKC-activating ligands, cer-
tain fatty acids such as arachidonate also have some acti-
vatory ability. Upon binding to PKC diacylglycerols increase
the affinity of the enzyme for Ca2". Research on PKC
gathered momentum when the specific cellular receptor via
which tumour promoting phorbol esters exerts its biological
effects was shown to be PKC (Nishizuka, 1988). Phorbol
esters, of which 12-O-tetradecanoylphorbol-13-acetate (TPA)
(Figure 1) is the most potent, are strong activators of PKC.
But they are much more resistant to metabolism than
diacylglycerols, and it is the protracted stimulation of PKC
by phorbol esters which is thought to trigger their effects,
including tumour promotion. A fateful but intrinsic conse-
quence of the sustained binding of biochemically stable
ligands such as phorbol esters to the enzyme is its eventual
demise in that they cause enzyme downregulation (Rodriguez-
Pena & Rozengurt, 1984). Binding to and downregulation of
PKC are at the heart of the specificity with which PKC
activators exert their effects and both undoubtedly determine
differences in efficacy between agents. There are several con-
troversial issues concerning the nature of the binding of
activators to PKC and the mechanism proper of activation,
and they have recently been cogently reviewed (Blumberg,
1991). Marked differences in binding affinity of TPA for its
receptor sites between the major PKC isozymes (a, P and y)
in vitro do not exist. But different phorbol esters do activate
PKC isozymes somewhat disparately, consistent with the
rigid structural control which governs their biological proper-
ties (Hecker, 1985; Brooks et al., 1989). Six phorbol esters
were recently investigated for their proficiency to activate
PKC-z, -P, -y, -S, or -e (Ryves et al., 1991). Four agents
were more or less indiscriminate in their effects on the
isozymes, but two showed interesting specificity. Sapintoxin
A (Figure 1) activated all isozymes except PKC-6, whereas
12-deoxyphorbol-13-O-phenylacetate-20-acetate (DOPPA)
(Figure 1) activated almost exclusively PKC-pl3. Also
arachidonate activated PKC-o, -P and --y differentially, depend-
ing on specific cofactors (Sekiguchi et al., 1989).
Examples of cells in which phorbol esters cause cytostasis
or cytotoxicity are MCF-7 breast, A431 epidermal and A549
lung carinoma cells (Gescher, 1985). Phorbol esters are also
growth inhibitors of several transformed melanoma lines in
culture, whereas normal melanocytes need the continual
presence of phorbol esters in order to grow (Becker et al.,
1990; Brooks et al., 1990), a finding indicative of a pro-
replicative role of PKC downregulation in this cell type (vide
supra). How phorbol esters arrest the growth of cells is
unclear, but cytostasis seems to be unquivocally linked to
PKC activation. Growth arrest caused by TPA in A549 cells
was dependent on the presence of foetal calf serum (Brad-
shaw et al., 1991), which suggests the involvement of positive
and/or negative growth factors. In actively dividing human
B-lymphoma cells efficient interruption of the cell cycle in
two places was a consequence of PKC activation (Beckwith
et al., 1990). In some cell lines, prominent among them the
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Figure 1 Structures of PKC activators.12 A. GESCHER
HL-60 promyelocytic leukaemia, the phorbol ester-induced
loss of proliferative potential is the result of induction of
differentiation (Vandenbark & Niedel, 1984). TPA-induced
differentation is often terminal, but in U-973 leukaemia cells
it is not, as after removal of phorbol esters cells undergo
retrodifferentiation (Hass et al., 1991). The search for the
discovery of nuclear events which trigger differentiation is on,
and the TPA-induced 'immediate early' and transient tran-
scription of a HL-60 cell gene has been reported (Shimizu et
al., 1991). It encodes a protein related to products of the jun
gene family.
One inevitable conclusion of the bewildering literature on
the nature and degree of response to PKC activation is that
phorbol ester effects are cell-type dependent (Weinstein,
1988). PKC isozyme heterogeneity (vide supra) could account
for this cell type specificity. Extrapolated to cells in which
PKC activation causes changes in growth this idea would
mean that certain PKC isozymes are responsible for mito-
genesis, others for growth arrest. If this was so an insight
into the specific roles and differential activation of PKC
isozymes might provide the key to unlock the understanding
of differential cellular responses to phorbol esters. Several
papers, especially some on the role of oncogenes in PKC
isozyme expression, hint at the contours of this key. Of the
three PKC isozymes a, P and y the P- form was by far the
most abundant in the cytosol of naive HL-60 cells, whereas it
was dramatically reduced in cells which had been rendered
resistant towards TPA-induced differentiation by continued
exposure to TPA (Nishikawa et al., 1990). TPA also
activated one of the two major PKC isoforms in HL-60 cells,
probably PKC-P, more effectively than the other, PKC-a
(Beh et al., 1989). These results are consistent with the
hypothesis that PKC-P is particularly important for induction
of differentiation. Accordingly expression of this isozyme, but
not of PKC-a, correlated with the responsiveness of KG-1
myeloid leukaemia cells to the differentiating effects of TPA
(Hooper et al., 1989), and 1,25-dihydroxyvitamin D3-induced
differentiation of HL-60 cells resulted in an increase of
predominantly PKC-P transcripts (Obeid et al., 1990). Rat
embryo fibroblasts and liver epithelial cell lines which were
transformed by an activated human c-Ha-ras oncogene dis-
played a several-fold increase in PKC-a and a concomitant
decrease in PKC-c, at both the protein and mRNA levels
(Borner et al., 1990). The authors tendered the intriguing
hypothesis that both, upregulation of PKC-a and down-
regulation of PKC-e, might be necessary for an activated ras
gene to accomplish its transforming function, perhaps
because PKC-m and PKC-s play reciprocal roles in cell
transformation, PKC-ax mediating mitogenic events, whereas
PKC-e having the opposite effect. These rat cells are not the
only system in which transformation by ras oncogenes causes
PKC modulation. Ha-ras or Ki-ras-transformed NIH 3T3
fibroblasts possess constitutively elevated diacylglycerol levels
with consequent partial activation and downregulation of
PKC (Wolfman & Makara, 1987), although the isozymes
involved have not been identified. The corollary of these
findings for therapy might ultimately be that treatment of
ras-transformed malignancies should aim at raising PKC-e
and/or inhibiting PKC- o activity. In view of the frequency of
mutated ras in human malignancies such an approach might
lead to broad-spectrum anticancer agents.
There is other evidence which supports the notion that
specific PKC activators might be of therapeutic value. Phor-
bol ester-induced progression of initiated cells to papillomas
and carcinomas was prevented by exposing cells to weak
promoting regimes using TPA prior to treatment to achieve
promotion proper (Reddy & Fialkow, 1990). This result
would suggest that modulation of specific PKC isozymes
with a high affinity activator might prevent the action of
tumour promoters. Overexpression ofPKC-P13 in HT29 colon
cancer cells caused growth inhibition in vitro (Choi et al.,
1990). These cells displayed decreased tumourigenicity when
grown in nude mice and, unlike control transformants which
lacked the PKC cDNA insert, were induced to differentiate
by TPA (Choi & Weinstein, 1991). These findings led to the
suggestion that in some tumours PKC might act as a growth
suppressor gene. It hs to be pointed out though that in many
other cell lines overexpression of PKC provokes the enhance-
ment rather than retardation of growth rate (Krauss et al.,
1989; Housey et al., 1988; Persons et al., 1988), which high-
lights the complex cell- and isozyme-specificity of events
catalysed by PKC.
Diacylglycerols have not shown the strong growth-inhibi-
tory properties in the cell lines in which phorbol esters are
cytostatic, perhaps due to their swift metabolic removal from
the site of action. Dioctanoylglycerol (Figure 1) was not an
efficacious inducer of HL-60 cell differentation (Morin et al.,
1987), nor did it cause cytostasis in MCF-7 (Valette et al.,
1987) or A549 cells (Laughton et al., 1989a) unless relatively
high cytotoxic concentrations were applied. Synthesis of
analogues of diacyglycerols, in which the diester moiety is
part of a ring structure to resemble ring C of the TPA
molecule, or with an alkylated glycerol backbone, did not
yield potent growth-inhibitory agents or compounds with
high affinity for PKC (Molleyres & Rando, 1988; Laughton
et al., 1989b).
In the above examples PKC activation is linked with cyto-
stasis more or less directly. Alternatively, PKC activators
could conceivably be beneficial in cancer treatment via
indirect mechanisms. PKC-mediated alteration of cellular
sensitivity to cytotoxic drugs was shown in human ovarian
carcinoma (Isonishi et al., 1990) and cervical carcinoma
(HeLa) cells (Basu et al., 1990). Both were rendered more
responsive to the antiproliferative effect of cis-diam-
minedichloroplatinum(II) (cis-DDP) by phorbol esters.
Analogues of the non-phorbol ester promoter lyngbyatoxin
A had a similar effect (Basu et al., 1991) and the ability of
these agents to sensitise cells to cis-DDP was correlated with
their ability to activate PKC. These findings invoke the pos-
sibility to overcome anticancer drug resistance in certain cells
with PKC activators which would restore' sensitivity. How-
ever this prospect does not seem to be generally applicable
and each cell type may have to be considered separately. In
colon cancer cells PKC activation has been shown to be
responsible for, or to contribute to, intrinsic drug resistance
(Dong et al., 1991). Multi-drug resistant human KB and
mouse sarcoma 180 cells contained significantly higher levels
of PKC-x than their drug-sensitive counterparts (Posada et
al., 1989) and inhibition of endogenous PKC activity in the
insensitive cells did not maintain or increase but decreased
resistance to adriamycin. Elevated PKC activity in cells as a
cause of decreased rather than increased sensitivity to
antitumour cytotoxicants has been explained by PKC-
mediated activation of gp 170, the product of the multi-drug
resistance gene MDR] (Ford & Hait, 1990). Adriamycin-
resistant HL-60 cells contained the same level of PKC-a but
less PKC-,B than their sensitive counterparts (Aquino et al.,
1990). Moreover they also possessed PKC-y, which was
absent in adriamycin-sensitive HL-60 cells. These results
underline the functional importance of specific PKC isoforms
in contrast to overall enzyme levels.
Regulation of PKC
Is specificity possible at the level of PKC regulation?
Mechanisms of PKC regulation are complex, but some are
amenable to interference by exogenous agents. Exposure of
cells to Ca2" or phorbol esters leads to the redistribution of
PKC from the cellular cytosol to the particulate subcellular
fraction (Kraft & Anderson, 1983). This association with
membranes is presumably normally mediated by diacylgly-
cerol and brings PKC into close proximity with its cofactor
phospholipid. Some selectivity was observed in Ca2+-medi-
ated PKC redistribution in rat pituitary cells (Kiley et al.,
1990). An increase in cytosolic Ca2" caused transcloation of
PKC-aand -13 but not of PKC-c. Changes in PKC localisa-
tion probably involve its binding to specific 'receptors for
activated C-kinase' (RACKs), which were proposed to exist
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(Mochley-Rosen et al., 1991). The PKC downregulation
observed on sustained exposure to PKC activating ligands is
probably due to an increased proteolytic degradation of PKC
by endogenous protease (Young et al., 1987; Pontremoli et
al., 1990). Differential kinetics of depletion of PKC isozymes
have been reported in several cellular systems (Huang et al.,
1989; Schaap et al., 1990; Ase et al., 1988; Adams & Gullick,
1989), indicating that the rate at which PKC is downregu-
lated is isoform- and cell type-specific. In rat pituitary cells
phorbol ester treatment caused a total loss of immunoreac-
tive PKC-,B and PKC-e, but only partial downregulation of
PKC-a (Kiley et al., 1990), which suggests that prolonged
exposure to phorbol esters might be a means to generate a
cell population containing mainly PKC-a. To complicate
matters downregulation of PKC-c, but not of PKC-P, by
TPA in thymocytes depended on elevated levels of Ca2"
(Strulovici et al., 1991). The rate at which PKC recovers after
long-term phorbol ester treatment is also isozyme-dependent
(Huwiler et al., 1991). In contrast to the original hypothesis
(Kraft & Anderson, 1983) events which cause PKC redistri-
bution and down-regulation, respectively, are probably not a
prelude to, or a corollary of, enzyme activation (Trilivas et
al., 1991; Pears & Parker; 1991; Lindner et al., 1991; Brad-
shaw et al., 1992). Therefore it is conceivable that agents will
eventually be found which affect PKC by interference with
enzyme redistribution, binding to RACKs, or enzyme down-
regulation, without being enzyme activators. This possibility
is particularly appealing in view of the finding that down-
regulation of PKC can elicit cytotoxicity in certain cell types.
TPA at concentrations provoking PKC down-regulation
killed neoplastic thyroid follicular cells which express a
mutant ras oncogene, but not normal follicular cells (Bond et
al., 1992).
That PKC isoenzymes can be regulated independently has
been shown in human leukaemia cell lines. When Jurkat
leukaemic T cells were grown continuously in the presence of
phorbol esters they exhibited a 6-fold decrease in
enzymatically active cytosolic PKC (Isakov et al., 1990). This
decrease was selective for PKC-a, whereas PKC-P or y were
not affected. The expression of the corresponding genes was
not changed. These results contrast with experiments in
which the PKC phenotype was compared between HL-60
cells and a subline PR-17 with acquired resistance to the
differentiating and cytostatic properties of TPA (McSwine-
Kennick et al., 1991). Crude preparations of the resistant
cells contained only 70% of PKC activity in wild type HL-60
cells, but other aspects of the PKC phenotype were equiva-
lent, among them the relative expression of the PKC-x and -,B
proteins. Both isozymes were downregulated similarly in
either cell line on exposure to TPA. However in the wild-type
cells steady state levels and transcriptional rates of PKC-P
mRNA were increased between 3 to 5-fold after incubation
with TPA for I to 2 days; similarly PKC-P gene transcription
was increased, whereas PKC-x mRNA was not affected.
These changes did not occur in the TPA-resistant PR-17
cells. This work suggests that specific alterations in the ex-
pression of the PKC-P gene (or of other genes regulated by
activated PKC isozymes) are important for the induction of
monocytic differentiation in HL-60 cells.
Molecular events which regulate PKC isozyme gene ex-
pression seem to be part of a complex hierarchy. This was
shown in NCI H209 human small cell lung cancer cells in
which co-insertion of a human c-myc and a viral Ha-ras gene
were associated with distinct changes in expression of PKC-a
and -P, both at the transcript and protein levels (Barr et al.,
1991). These changes accompanied the adoption by the cells
of morphological properties of large cell carcinoma. In naive
NCI H209 cells PKC-a was the dominant PKC species.
Expression of the myc gene, but not of the ras gene, caused a
5- to 10-fold increase in the PKC-P isoform transcript and
protein. Coinsertion of ras and myc reversed the increased
PKC-P transcript levels induced by myc alone and also
elicited the redistribution of PKC-Pprotein from the cytosol
to the membrane and a decrease in membrane-associated
PKC-.
Bryostatins
The byrostatins are macrocyclic lactones isolated from
marine bryozoans, of which 17 different derivatives have
been described (Pettit, 1991). They activate PKC, in some
cells as potently as TPA, in others somewhat less strongly
(Berkow & Kraft, 1985; Smith et al., 1985), and bryostatin 1
was able to displace phorbol esters from their receptors in a
semi-purified rat brain PKC preparation at subnanomolar
concentrations (De Vries et al., 1988). A weak structural
similarity exists between the bryostatin and phorbol ester
molecules as revealed by computer modelling of the spatial
arrangement of sets of several oxygen atoms (Wender et al.,
1988). The current clinical trials of bryostatin 1 have been
initiated mainly on the basis of its interesting antineoplastic
activity in rodent models. Inhibition of cell proliferation by
bryostatins has been demonstrated in vitro in a variety of
murine tumour cell lines traditionally used as antitumor drug
screens (Pettit et al., 1982), also in M5076 reticulum cell
sarcoma, B16 melanoma and LIOA B-cell lymphoma (Hor-
nung et al., 1992), and in human chronic myelomonocytic
leukaemia cells (Lilly et al., 1991). They have displayed
antitumour activity in vivo on multiple i.p. administration in
mice with P388 lymphocytic leukaemia, ovarian sarcoma
(Pettit et al., 1970), B16 melanoma (Schuchter et al., 1991),
M5076 sarcoma and LIOA lymphoma (Hornung et al., 1992).
Significantly, TPA was not cytostatic in the B16 melanoma
model. Bryostatins are potent immunomodulators, they
activate T-cells, augment neutrophil- and monocyte-mediated
cytotoxicity and stimulate bone marrow progenitor cells
(Hess et al., 1988; May et al., 1987). A truly puzzling feature
of their biological activity is its paradoxical nature. In many
cell lines they are not only agonistic with tumour-promoting
phorbol esters but also able to antagonise biochemical res-
ponses elicited by themselves or by phorbol esters. They
mimic TPA in that they inhibited phorbol ester binding and
caused mitogenesis in Swiss 3T3 cells (Smith et al., 1985),
stimulated human polymorphonuclear leukocytes (Berkow &
Kraft, 1985), and induced ornithine decarboxylase, while
inhibiting cell-cell communication in keratinocytes (Sako et
al., 1987; Pasti et al., 1988). They also inhibited the growth
of A549 cells, albeit only for a period of 24 h, beyond which
growth inhibition was slowly reversed (Dale & Gescher, 1989).
Bryostatin 1 failed to induce terminal differentiation of
human colon cancer (McBain et al., 1988) and of HL-60 cells
(Kraft et al., 1986). Nevertheless morphological or functional
evidence of incomplete differentiation was noticed in most of
these lines on exposure to bryostatin. In contrast, bryostatins
blocked the differentiation induced by phorbol esters in HL-
60 (Kraft et al., 1986), human colon cancer (McBain et al.,
1988) and primary mouse epidermal cells (Sako et al., 1987).
They also restored the differentiation response in Friend
erythroleukaemia cells, in which drug-induced differentiation
was suppressed by phorbol esters (Dell'Aquila et al., 1987).
Bryostatin 1 blocked both the inhibitory effects on growth
elicited by lower concentrations of itself or by TPA (Dale &
Gescher, 1989). Similarly, when combined with TPA bryo-
statin prevented the TPA-induced inhibition of proliferation
of GH4C1 in rat pituitary tumour cells (Mackanos et al.,
1991). Relevant to the prospective use of bryostatin 1 in the
clinic is the finding that it lacked tumour-promoting proper-
ties in the SENCAR mouse model, indeed it inhibited TPA-
induced tumour promotion (Hennings et al., 1987). The
conclusion to be drawn from the perplexing literature on
bryostatins is that they exert some of their effects via
mechanisms which are independent of those operated by
phorbol esters. In none of the above examples was there any
evidence that the paradoxical effects were accompanied by
paradoxical consequences on PKC redistribution or down-
regulation (Dale et al., 1989). Therefore the ability of the
byrostatins to antagonise certain phorbol ester effects sug-
gests that they interfere with events downstream of PKC
activation. Alternatively certain isozymes like PKC-G or other
cellular signal transduction mechanisms not activated by
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tion pattern in cells exposed to either bryostatins or phorbol
esters are consistent with this hypothesis. In HL-60 cells
bryostatin 1 caused the phosphorylation of two 70 kDa pro-
teins, perhaps of cytoskeletal origin, in addition to those
which were phosphorylated in the presence of phorbol
dibutyrate (Warren et al., 1988). The bryostatin-specific re-
sponse could also be evoked by concentrations of phorbol
dibutyrate which exceeded that necessary to induce differenti-
ation by a factor of 100. This finding underlines the possi-
bility that bryostatins and high concentrations of phorbol
esters affect specific PKC isoforms differently from phorbol
esters at low concentrations. Bryostatin 1 was less efficient
than TPA in competing for specific phorbol ester receptor
sites ofisolated PKC-P, whereas it equalled TPA in its ability
to bind to PKC-a and -' (Kraft et al., 1988). A significant
difference between bryostatins and TPA may be the direction
of PKC redistribution. Treatment of HL-60 cells with bryo-
statin I led to the specific redistribution of activated PKC-Pll,
but not of PKC-x to the nuclear envelope, where it triggered
the phosphorylation of the polypeptide lamin B (Fields et al.,
1988). In contrast, phorbol dibutyrate caused PKC redist-
ribution towards the plasma membrane (Fields et al., 1988).
Such a discrepancy in PKC relocalisation has yet to be
reported for cell lines other than HL-60, in which the bryos-
tatins and phorbol esters possess antagonistic properties.
Table I PKC inhibitors
A. at the catalytic domain
Staurosporine
Hydroxystaurosporine
UCN-01
N-Benzoylstaurosporine CGP
41251
K252a
H-7
Aminoacridine
Sangivamycin
Chelerythrine
Suramin
Dequalinium
Protein PKCI-I
B. at the regulatory domain:
Calphostin C
Chlorpromazine
Trifluoperazine
Ether lipids
Hexadecylphosphocholine
Tamoxifen
Sphingosine
Trimethylsphingosine
Adriamycin
(R)-Niguldipine
NPC 15437
(Tamaoki et al., 1986)
(Akinage et al., 1991)
(Meyer et al., 1989)
(Kase et al., 1987)
(Hidaka et al., 1984)
(Hannun & Bell, 1988)
(Lomis & Bell, 1988)
(Herbert et al., 1990)
(Mahoney et al., 1990)
(Rotenberg et al., 1990)
(Pearson et al., 1990)
(Kobayashi et al., 1989)
(Mori et al., 1983)
(Wise & Kuo, 1983)
(Marx et al., 1988)
(Uberall et al., 1991a; Geilen
et al., 1991)
(O'Brian et al., 1985)
(Hannun & Bell, 1987)
(Endo et al., 1991)
(Hannun et al., 1989)
(Oberall et al., 1991b)
(Sullivan et al., 1991)
PKC inhibitors and growth arrest
In view of the role of PKC in the mediation of mitogenic
signals the concept of inhibiting rather than activating PKC
appears to be the more logical strategy in the search for
novel avenues in cancer treatment. In support of this idea
aberrant expression of PKC has been associated with certain
malignancies and metastasis. Transfection of a mutant PKC-x
gene into BALB/c 3T3 fibroblasts enhanced their tumouri-
genicity (Megidish & Mazurek, 1989), but this finding has
subsequently been disputed (Borner et al., 1991). Metastatic
potential has also been correlated with overexpression of
normal PKC (Persons et al., 1988; Housey et al., 1988).
Which are the sites within PKC which could be considered
as targets for the design of inhibitors, and which degree of
selectivity do they allow? There are firstly the regulatory
domain, which contains the activator binding site, secondly
the ATP binding site on the catalytic domain, and thirdly the
substrate binding domain. A priori the chance of selectivity
seems to be lowest in the case of inhibitors of the ATP
binding site, as it shows strong homology with other serine
and tyrosine kinases. Specificity seems more likely for agents
which inhibit predominantly at the regulatory site, and even
more possible in the case of inhibitors of the substrate bind-
ing site. Examples of agents which inhibit PKC by interac-
tion with the regulatory or catalytic domains are listed in
Table I. On the whole their specificity for PKC is moderate.
Therefore it is unclear whether their cytostatic potential is
mediated via PKC, other kinases or a combination. Impor-
tant in the context of this discussion is that potent PKC
inhibitors do possess growth-inhibitory or cytotoxic proper-
ties (Tamaoki & Nakano, 1990). Thus properties of two
representative molecules, staurosporine and sphingosine
(Figure 2), are briefly described in the following. Stauros-
porine, an indole carbazole, inhibits at the catalytic domain
and is one of the most potent PKC inhibitors yet described
(Tamaoki et al., 1986), and sphingolipids are natural cons-
tituents of cells and inhibit the regulatory domain (Hannun
& Bell, 1989). Staurosporine showed an effect on tumour cell
invasion and is thus of potential therapeutic interest. At
non-toxic concentrations it antagonised the invasion of
human bladder carcinoma cells through an artificial base-
ment membrane by inhibiting cell motility (Schwartz et al.,
1990). The drug displayed an unexpected element of
specificity in that it affected cell cycle progression and nuclear
morphology differently in MOLT-4 human lymphocytic
leukaemia cells as compared to normal human lymphocytes
(Bruno et al., 1992). Minor structural modifications have
yielded derivatives with greater selectivity for PKC. N-
Benzoylstaurosporine CGP 41251 (Figure 2) is a less potent
but more selective PKC inhibitor than staurosporine (Meyer
et al., 1989). Both agents had comparable antitumour activity
against a human bladder carcinoma xenograft grown in nude
mice. Likewise RO 31-8220 and RO 31-7549 (Figure 2),
cogeners of the staurosporine aglycone, were more specific
PKC inhibitors than staurosporine in vitro (Davis et al.,
1989) and in intact cells (Dieter & Fitzke, 1991). UCN-01,
hydroxystaurosporine (Figure 2), is a more selective but
weaker and less cytotoxic PKC-inhibitor than staurosporine.
But unlike staurosporine, it displayed antineoplastic activity
against three human tumour xenografts in nude mice and
two murine models, all of which possessed certain aberra-
tions in cellular signal transduction (Akinaga et al., 1991). As
is the case with the bryostatins, staurosporine displays
paradoxical effects in that it not only inhibits but also mimics
certain phorbol ester effects. Staurosporine enhanced TPA-
induced responses in mouse keratinocytes, such as cellular
maturation (Dlugosz & Yuspa, 1991). It was also a weak
tumour promoter in the CD-1 mouse model, even though it
inhibited promotion induced by phorbol esters (Yoshizawa et
al., 1990). There is an indication that inhibitors of the
staurosporine type do not repress all PKC isoforms equally,
as a Ca2"-independent PKC isoform from porcine spleen was
unaffected by the staurosporine analogue K252a (Gschwendt
et al., 1989).
Lysophingolipids such as sphingosine (Figure 2) are
metabolites ofmembrane sphingolipids which may be cellular
second messengers (Hannun & Bell, 1989). Sphingosine
inhibited the TPA-induced differentiation of HL-60 cells
(Merrill et al., 1989), and dihydrosphingosine in the 10-6 M
concentration range exerted cytostasis and cytotoxicity
against Chinese hamster ovary cells (Stevens et al., 1990).
Both effects were mechanistically attributed to PKC inhibi-
tion, which seems to require pH conditions under which the
sphingosine amine function is protonated (Bottega et al.,
1989). Unlike sphingosine itself, its synthetic analogues N,N-
dimethyl- and N,N,N-trimethyl-sphingosine (Figure 2) had
moderate antineoplastic activity in vivo against a human
gastric carcinoma cell line grown in nude mice (Endo et al.,
1991), and the latter also inhibited the metastatic potential of
murine B16 melanoma cells in vivo (Okoshi et al., 1991). Of
the anticancer drugs in clinical use which possess PKC-
inhibitory properties (Table I) the most remarkable is tam-
oxifen. This drug and its metabolites interact with thePHARMACOLOGICAL MODULATION OF PROTEIN KINASE C 15
R,R2,=H Staurosporine
R1= OH, R2= H UCN-01
R1= H,R2= benzoyl CPG41251
OH
CH3(CH2)12 CH20H
K2
R1,R2,R3 = H Sphingosine
R1,R2,=CH3,R3 = H Dimethylsphingosine
R,,R2,R3= CH3 Trimethylsphingosine
Figure 2 Structures of PKC inhibitors.
regulatory domain of PKC and inhibit the enzyme at phar-
macologically relevant concentrations in the 10-5 M range
(O Brian et al., 1985). PKC inhibition might contribute to its
mechanism of antineoplastic action.
The regulatory domain of PKC contains a sequence with a
cluster of basic residues, which resembles PKC phosphoryla-
tion sites, except that the potential phosphate acceptor serine
is replaced by alanine (House & Kemp, 1987). Binding of this
'pseudosubstrate' to the substrate binding domain is thought
to be responsible for the maintenance of inactive PKC in the
absence of an activating molecule. A synthetic peptide corres-
ponding to this sequence, Arg-Phe-Ala-Arg-Lys-Gly-Ala-
Leu-Arg-Gln-Lys-Asn-Val, turned out to be an inhibitor of
exquisite specificity for PKC in isolated enzyme preparations
(House et al., 1987) and permeabilised cells (Eichholtz et al.,
1990). Manipulations to achieve intracellular delivery of this
or similar pseudosubstrates and to restrain their proteolytic
destruction might furnish exciting molecules with a better
chance of specificity than that displayed by the compounds
shown in Table I.
None of the PKC inhibitors so far discovered are partic-
ularly selective with respect to PKC isozymes. Nevertheless
isozyme-specificity was demonstrated when PKC was irrever-
sibly destroyed by acidic phospholipids in incubates lacking
divalent cations (Huang & Huang, 1990; Pelosin et al., 1990).
Of the three major PKC isozymes, PKC-y was the most and
PKC-a the least susceptible to this inactivating effect. As it
seems to depend on rather artificial in vitro conditions it is
unlikely to be exploitable in intact cells.
A further example of the complex nature of pharma-
cological modulation of PKC activity is the activity of the
experimental antineoplastic alkyllysophospholipid ET-18-
OCH3 (Figure 2), a synthetic analogue of2-lysophosphatidyl-
choline. ET-18-OCH3 inhibited PKC purified from HL-60
cells with a Ki of 9-1l5M (Zheng et al., 1990), and the
inhibition was competitive with respect to phosphatidylserine.
In contrast, the drug activated PKC instead of inhibiting it
when the enzyme was prepared from HL-60 cells such that it
was still associated with the plasma membrane (Heesbeen et
al., 1991).
R = (CH2)3NH2 RO 31-7549
R =(CH2)3S-C-NH2RO 31-8220
NH
NH
H3C,, CH3 0 NC/
H3 11
CH OoI 0 O(CH2)17CH3 3 O- OCH3
ET-18-OMe
Conclusions
Because of its pivotal importance for signal transduction
mechanisms PKC is undoubtedly a logical target for drug
intervention. Subtle differences in terms of levels and
heterogeneity of PKC between normal and neoplastic tissues
and between different neoplasias are beginning to emerge.
These differences might provide selective targets for rational
drug design. Among the PKC isozymes the P-form seems to
play a crucial role in differentiation, and the design of
differentiation inducers should perhaps target PKC-1. In ras-
transformed malignancies PKC-o might mediate mitogenic
and PKC-c anti-mitogenic events. The selective physio-
logical roles of these and other PKC subforms will
undoubtedly become clearer soon. Pharmacological alteration
of the balance between different PKC isoforms might turn
out to be as critical for cell dynamics as modification of a
specific PKC isoform.
The nature and extent of effects of some of the cytostatic
PKC modulators described above are paradoxical and con-
fusing. This might be related to the fact that the functional
consequence of PKC modulation seems to be different for
each cell type and that the specific roles of PKC isozymes
might be cell type-specific. It appears that in order to be of
therapeutic value PKC modulators need to be more selective
than the currently known agents. Details of the mechanistic
link between the growth-inhibitory properties of these agents
and the extent of their ability to modulate PKC are still
essentially unknown. Bryostatin 1 activates PKC but also
antagonises phorbol esters; staurosporine is a potent
inhibitor but also exerts phorbol ester-agonistic effects; ET-
18-OCH3 is a PKC inhibitor, but under certain conditions an
activator. They all mobilise mechanisms yet to be understood
in addition to gross PKC modulation. Nevertheless selective
pharmacological intervention with PKC-related process
might eventually be possible, as isozymes selectivity among
PKC activators seems to be no longer an elusive goal. The
phorbol esters sapintoxin A and DOPPA are 'lead com-
pounds' in this respect. Inhibitors like staurosporine lack
selectivity, but chemical modification has already furnished16 A. GESCHER
molecules with increased selectivity for PKC and increased
experimental antineoplastic properties compared to the
parent molecule. PKC pseudosubstrate analogues might offer
even better specificity.
There is no doubt that the complicated interaction between
different second messenger signalling systems which involve
cascades of kinases, one of which is PKC, will render selec-
tive drug action using PKC modulators difficult. Whether it
is too complex for therapeutic intervention remains to be
seen.
Note added in proof
'In MCF-7 cells, the growth of which is inhibited by TPA
but only marginally by bryostatin 1, cytosolic PKC-o was
down-regulated by bryostatin 1 without any observable redis-
tribution to the membrane, whereas TPA caused PKC-a
redistribution before it was down-regulated (Kennedy et al.,
1992). A cogent model which describes common structural
features of PKC activators including the bryostatins has very
recently been described (Rando & Kishi, 1992)'.
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